Aarts, Jip
Saddal, Shalina R. D.
Bosmans, Judith E.
de Groot, Vincent
de Jong, Brigit A.
Klein, Martin
Ruitenberg, Marit F. L.
Schaafsma, Frederieke G.
Schippers, Esther C. F.
Schoonheim, Menno M.
Uitdehaag, Bernard M. J.
van der Veen, Sabina
Waskowiak, Pauline T.
Widdershoven, Guy A. M.
van der Hiele, Karin
Hulst, Hanneke E.
den Teuling, Bram A. J.
van Oirschot, Pim
Cloosterma, Sonja
Vermeer, Jos
Schouten, Chris C.
Stege, Gerard J.
van ’t Hullenaar, Thijs
van Munster, Casper E. P.
Wieberdink, Renske G.
Schouten, Jolijn Kragt Judith
Hoogervorst, Erwin L. J.
Bouma, Paul A. D.
De Kleermaeker, Floris G. C. M.
Holleman, Meike
Geurts, Sofie
de Brabander, Christaan
Kalkers, Nynke F.
,
Funding for this research was provided by:
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWA.1292.19.064, NWA.1292.19.064, NWA.1292.19.064, NWA.1292.19.064, NWA.1292.19.064, NWA.1292.19.064, NWA.1292.19.064, NWA.1292.19.064, NWA.1292.19.064, NWA.1292.19.064, NWA.1292.19.064, NWA.1292.19.064, NWA.1292.19.064, NWA.1292.19.064, NWA.1292.19.064, NWA.1292.19.064)
Article History
Received: 5 December 2023
Accepted: 17 December 2023
First Online: 15 January 2024
Declarations
:
: The study has been approved by the medical ethics review committee of Amsterdam University Medical Centers (METc 2023.0613, protocol version 3 date 16–02-2023). Any future substantial changes to the protocol will undergo review and approval by the medical ethics review committee. This study will be carried out according to the Declaration of Helsinki. The study is registered at ClincialTrials.gov with registration number NCT06068582. Written informed consent for publication of results will be obtained from all participants.
: Not applicable.
: JA, SS, JB, VG, BJ, MK, MR, FS, ES, SV, PW, GW, and KH have nothing to declare with respect to this study.BU has received research support and/or consultancy fees from Biogen Idec, Genzyme, Merck Serono, Novartis, Roche, Teva and Immunic Therapeutics.MS serves on the editorial board of Neurology, Multiple Sclerosis Journal and Frontiers in Neurology, receives research support from the Dutch MS Research Foundation, Eurostars-EUREKA, ARSEP, Amsterdam Neuroscience, MAGNIMS and ZonMW (Vidi grant, project number 09150172010056) and has served as a consultant for or received research support from Atara Biotherapeutics, Biogen, Celgene/Bristol Meyers Squibb, EIP, Sanofi, MedDay and Merck.HH is an editor of the Multiple Sclerosis Journal controversies sections, receives research support from the Dutch MS Research Foundation and the Dutch Research Council. She has served as a consultant for or received research support from Atara Biotherapeutics, Biogen, Novartis, Celgene/Bristol Meyers Squibb, Sanofi Genzyme, MedDay and Merck BV.